Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
Identifieur interne : 000061 ( PubMed/Corpus ); précédent : 000060; suivant : 000062Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
Auteurs : Patrick Rossignol ; Faiez Zannad ; Bertram PittSource :
- International journal of cardiology [ 1874-1754 ] ; 2014.
English descriptors
- KwdEn :
- Aminobutyrates (pharmacology), Aminobutyrates (therapeutic use), Angiotensin Receptor Antagonists (pharmacology), Angiotensin Receptor Antagonists (therapeutic use), Heart Failure (blood), Heart Failure (drug therapy), Humans, Mineralocorticoid Receptor Antagonists (pharmacology), Mineralocorticoid Receptor Antagonists (therapeutic use), Randomized Controlled Trials as Topic (methods), Registries, Renin-Angiotensin System (drug effects), Renin-Angiotensin System (physiology), Stroke Volume (drug effects), Stroke Volume (physiology), Tetrazoles (pharmacology), Tetrazoles (therapeutic use), Time Factors.
- MESH :
- chemical , pharmacology : Aminobutyrates, Angiotensin Receptor Antagonists, Mineralocorticoid Receptor Antagonists, Tetrazoles.
- chemical , therapeutic use : Aminobutyrates, Angiotensin Receptor Antagonists, Mineralocorticoid Receptor Antagonists, Tetrazoles.
- blood : Heart Failure.
- drug effects : Renin-Angiotensin System, Stroke Volume.
- drug therapy : Heart Failure.
- methods : Randomized Controlled Trials as Topic.
- physiology : Renin-Angiotensin System, Stroke Volume.
- Humans, Registries, Time Factors.
Abstract
Numerous registries, including the most recent ESC Euro-observational registry, have reported a large and persistent gap between real-life practice in the use of life-saving evidence-based therapies (such as renin angiotensin antagonists, beta-blockers, mineralocorticoid receptor antagonists) and recommended practices in international guidelines. Although the use of multiple renin angiotensin aldosterone system-inhibitors is associated with the development of worsening renal function and hyperkalemia in patients with heart failure and reduced ejection fraction, increased efforts should be expended to initiate and maintain target doses of these agents so as to provide their benefits on mortality and hospitalizations for heart failure.
DOI: 10.1016/j.ijcard.2014.11.004
PubMed: 25465821
Links to Exploration step
pubmed:25465821Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.</title><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation><nlm:affiliation>Inserm, Centre d'Investigations Cliniques-Plurithématique 1433, Inserm U1116, Nancy, France; CHU Nancy, Département de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France; Université de Lorraine, France; INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), France. Electronic address: p.rossignol@chu-nancy.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation><nlm:affiliation>Inserm, Centre d'Investigations Cliniques-Plurithématique 1433, Inserm U1116, Nancy, France; CHU Nancy, Département de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France; Université de Lorraine, France; INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), France.</nlm:affiliation></affiliation></author><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation><nlm:affiliation>University of Michigan School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25465821</idno><idno type="pmid">25465821</idno><idno type="doi">10.1016/j.ijcard.2014.11.004</idno><idno type="wicri:Area/PubMed/Corpus">000061</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000061</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.</title><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation><nlm:affiliation>Inserm, Centre d'Investigations Cliniques-Plurithématique 1433, Inserm U1116, Nancy, France; CHU Nancy, Département de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France; Université de Lorraine, France; INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), France. Electronic address: p.rossignol@chu-nancy.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation><nlm:affiliation>Inserm, Centre d'Investigations Cliniques-Plurithématique 1433, Inserm U1116, Nancy, France; CHU Nancy, Département de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France; Université de Lorraine, France; INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), France.</nlm:affiliation></affiliation></author><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation><nlm:affiliation>University of Michigan School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International journal of cardiology</title><idno type="eISSN">1874-1754</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aminobutyrates (pharmacology)</term><term>Aminobutyrates (therapeutic use)</term><term>Angiotensin Receptor Antagonists (pharmacology)</term><term>Angiotensin Receptor Antagonists (therapeutic use)</term><term>Heart Failure (blood)</term><term>Heart Failure (drug therapy)</term><term>Humans</term><term>Mineralocorticoid Receptor Antagonists (pharmacology)</term><term>Mineralocorticoid Receptor Antagonists (therapeutic use)</term><term>Randomized Controlled Trials as Topic (methods)</term><term>Registries</term><term>Renin-Angiotensin System (drug effects)</term><term>Renin-Angiotensin System (physiology)</term><term>Stroke Volume (drug effects)</term><term>Stroke Volume (physiology)</term><term>Tetrazoles (pharmacology)</term><term>Tetrazoles (therapeutic use)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Aminobutyrates</term><term>Angiotensin Receptor Antagonists</term><term>Mineralocorticoid Receptor Antagonists</term><term>Tetrazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Aminobutyrates</term><term>Angiotensin Receptor Antagonists</term><term>Mineralocorticoid Receptor Antagonists</term><term>Tetrazoles</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Renin-Angiotensin System</term><term>Stroke Volume</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Renin-Angiotensin System</term><term>Stroke Volume</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Registries</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Numerous registries, including the most recent ESC Euro-observational registry, have reported a large and persistent gap between real-life practice in the use of life-saving evidence-based therapies (such as renin angiotensin antagonists, beta-blockers, mineralocorticoid receptor antagonists) and recommended practices in international guidelines. Although the use of multiple renin angiotensin aldosterone system-inhibitors is associated with the development of worsening renal function and hyperkalemia in patients with heart failure and reduced ejection fraction, increased efforts should be expended to initiate and maintain target doses of these agents so as to provide their benefits on mortality and hospitalizations for heart failure.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25465821</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>02</Day></DateCreated><DateCompleted><Year>2015</Year><Month>09</Month><Day>09</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>177</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int. J. Cardiol.</ISOAbbreviation></Journal><ArticleTitle>Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.</ArticleTitle><Pagination><MedlinePgn>731-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2014.11.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(14)02146-9</ELocationID><Abstract><AbstractText>Numerous registries, including the most recent ESC Euro-observational registry, have reported a large and persistent gap between real-life practice in the use of life-saving evidence-based therapies (such as renin angiotensin antagonists, beta-blockers, mineralocorticoid receptor antagonists) and recommended practices in international guidelines. Although the use of multiple renin angiotensin aldosterone system-inhibitors is associated with the development of worsening renal function and hyperkalemia in patients with heart failure and reduced ejection fraction, increased efforts should be expended to initiate and maintain target doses of these agents so as to provide their benefits on mortality and hospitalizations for heart failure.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rossignol</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Inserm, Centre d'Investigations Cliniques-Plurithématique 1433, Inserm U1116, Nancy, France; CHU Nancy, Département de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France; Université de Lorraine, France; INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), France. Electronic address: p.rossignol@chu-nancy.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zannad</LastName><ForeName>Faiez</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm, Centre d'Investigations Cliniques-Plurithématique 1433, Inserm U1116, Nancy, France; CHU Nancy, Département de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France; Université de Lorraine, France; INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pitt</LastName><ForeName>Bertram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Writing group of 10th Global Cardio Vascular Clinical Trialist forum held on December 6th-7th 2013 in Paris, France</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000613">Aminobutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C549068">LCZ 696</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000451">Mineralocorticoid Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000613">Aminobutyrates</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D057911">Angiotensin Receptor Antagonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000451">Mineralocorticoid Receptor Antagonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016032">Randomized Controlled Trials as Topic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012042">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012084">Renin-Angiotensin System</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013318">Stroke Volume</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013777">Tetrazoles</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Kidney function</Keyword><Keyword MajorTopicYN="N">Potassium</Keyword><Keyword MajorTopicYN="N">Renin angiotensin aldosterone system inhibition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25465821</ArticleId><ArticleId IdType="pii">S0167-5273(14)02146-9</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2014.11.004</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000061 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000061 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25465821
|texte= Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25465821" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a InforLorV4
| This area was generated with Dilib version V0.6.33. |  |